Vitruvias Therapeutics Thyroid Tablets 30 mg recalled for super potency risk
Vitruvias Thyroid Tablets recalled for super potency risk
Vitruvias Therapeutics is recalling one lot (504950) of Thyroid Tablets, USP 30 mg because testing found the tablets may contain higher-than-intended amounts of thyroid hormone. Taking overly potent thyroid medication can cause an overactive thyroid, leading to weight loss, rapid heartbeat, chest pain, and other serious symptoms, especially in elderly people, pregnant women, and infants.
- Check if your Thyroid Tablets are from lot 504950 (expiration 9/30/2026).
- Do not stop taking your medication without calling your doctor first—they can provide guidance or a replacement prescription.
- Contact your healthcare provider if you have experienced symptoms like weight loss, rapid heartbeat, chest pain, or heat intolerance.
- Call Vitruvias Therapeutics at (256) 239-9373 (Mon–Fri, 9 a.m.–5 p.m. CT) or email safety@vitruvias.com with questions about the recall.
Product photos
AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics, Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.
Official notice
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potentialDon't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief